Costing analysis of national hiv treatment and care program in vietnam

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 1, 2014, Pages

  Duong, Anh Thuy ^a   Kato, Masaya ^b   Bales, Sarah ^a,c   Do, Nhan Thi ^a   Nguyen, Thu Thi Minh ^b   Cao, Thuy Thi Thanh ^d   Nguyen, Long Thanh ^a  

^a MINISTRY OF HEALTH   (Viet Nam)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL HOSPITAL FOR TROPICAL DISEASES   (Viet Nam)

Author keywords

Antiretroviral therapy; Costing; HIV care; Integration; Vietnam

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; DONOR; DRUG COST; GOVERNMENT; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OUTPATIENT CARE; PATIENT CARE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIET NAM;

ADULT; AGE FACTORS; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG COSTS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HOSPITALIZATION; HUMANS; MALE; NATIONAL HEALTH PROGRAMS; VIETNAM;

EID: 84893774467     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182a17d15     Document Type: Article

References (20)

1. Government of Vietnam. Vietnam AIDS Response Progress Report 2012. Hanoi, Vietnam: National Committee for AIDS, Drugs and Prostitution Prevention and Control; 2012.
2. World Bank. Vietnam overview. Available at: http://www.worldbank. org/en/country/vietnam/overview. Accessed December 27, 2012.
3. Do TN, Nguyen TM, Do MH, et al. Combining cohort analysis and monitoring of HIV early-warning indicators of drug resistance to assess antiretroviral therapy services in Vietnam. Clin Infect Dis. 2012;54(suppl 4): S306-S312.
4. Leisegang R, Cleary S, Hislop M, et al. Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis. PLoS Med. 2009;6:e1000189.
5. Lewis MA, La Forgia GM, Sulvetta MB. Measuring public hospital costs: empirical evidence from the Dominican Republic. Soc Sci Med. 1996;43:221-234.
6. Shepard DS, Hodgkin D, Anthony YE. Analysis of Hospital Costs: A Manual for Managers. Geneva, Switzerland: World Health Organization; 2000.
7. Governemnt Statistic Office of Vietnam. Key indicators on National Accounts. 2012. Available at: http://www.gso.gov.vn/default-en.aspx? tabid=468&idmid=3&ItemID=12981. Accessed October 16, 2012.
8. WHO. Patient Monitoring Guidelines for HIV Care and Antiretroviral Therapy (ART). Geneva, Switzerland: World Health Organization; 2006.
9. Galarraga O, Wirtz VJ, Figueroa-Lara A, et al. Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low-and middle-income countries. Pharmacoeconomics. 2011;29:579-599.
10. Menzies NA, Berruti AA, Berzon R, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS. 2011; 25:1753-1760.
11. Sweeney S, Obure CD, Maier CB, et al. Costs and efficiency of integrating HIV/AIDS services with other health services: a systematic review of evidence and experience. Sex Transm Infect. 2012;88:85-99.
12. Fleishman JA, Yehia BR, Moore RD, et al. The economic burden of late entry into medical care for patients with HIV infection. Med Care. 2010; 48:1071-1079.
13. Levy A, Johnston K, Annemans L, et al. The impact of disease stage on direct medical costs of HIV management: a review of the international literature. Pharmacoeconomics. 2010;28(suppl 1):35-47.
14. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006;42:1003-1010.
15. Hogg RS, Yip B, Chan KJ, et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA. 2001;286:2568-2577.
16. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010; 363:257-265.
17. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363.
18. Nguyen DB, Do NT, Shiraishi RW, et al. Outcomes of antiretroviral therapy in Vietnam: results from a national evaluation. PLoS ONE. 2013;8:e55750.
19. Walensky RP, Wood R, Ciaranello AL, et al. Scaling up the 2010 World Health Organization HIV treatment guidelines in resource-limited settings: a model-based analysis. PLoS Med. 2010;7:e1000382.
20. Kato M, Granich R, Bui DD, et al. The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission. J Acquir Immunodefic Syndr. 2013; 63:e142-e149.